CERo Therapeutics Holdings, Inc. CERO
$0.01
$0.004.00%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -15.83% | -33.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.62% | 6.93% | |||
| Operating Income | 20.62% | -6.93% | |||
| Income Before Tax | 82.52% | -29.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 82.52% | -29.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 82.52% | -29.63% | |||
| EBIT | 20.62% | -6.93% | |||
| EBITDA | 20.82% | -7.16% | |||
| EPS Basic | -241.18% | 93.67% | |||
| Normalized Basic EPS | 11.84% | 32.21% | |||
| EPS Diluted | -241.18% | 93.67% | |||
| Normalized Diluted EPS | 11.84% | 32.21% | |||
| Average Basic Shares Outstanding | 46.67% | 91.92% | |||
| Average Diluted Shares Outstanding | 46.67% | 91.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||